Competition watchdog fines big pharma duo £70m

The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Swiss watchdog investigates Novartis over patent use

20 September 2022 Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

Big Pharma

CMA costs case improves access to justice

30 June 2022 The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.

Big Pharma

UK regulators no longer exempt from paying successful parties' costs

26 May 2022 The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Competition watchdog fines big pharma duo £70m

More on this story

Editor's picks

Editor's picks

More features